Behavioural effects and regulation of PKCα and MAPK by huprine X in middle aged mice

Pharmacology Biochemistry and Behavior

Volumn 95, Issue 4, 2010, Pages 485-493

  Ratia, M ^a   Gimenez Llort L ^a   Camps, P ^b   Munoz Torrero D ^b   Clos, M V ^a   Badia, A ^a  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acetylcholinesterase inhibitors; Aging; Amyloid precursor protein (APP); Huprine X; Learning and memory activation; Mitogen activated protein kinase (MAPK); Protein kinase C (PKC )

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; CHOLINESTERASE INHIBITOR; HUPRINE X; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMOTIONALITY; ENZYME REGULATION; LEARNING; MALE; MAZE TEST; MEMORY; MOTOR ACTIVITY; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALIA; MUS;

EID: 77952550378     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.03.013     Document Type: Article

References (46)

1. Adem A., Jossan S.S., Oreland J. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 1989, 107:313-317.
2. Alkon D.L., Rasmussen H. Spatial-temporal model of cell activation. Science 1988, 239:998-1005.
3. + channel cascade. Trends Neurosci 1998, 21:529-537.
4. Alkon D.L., Sun M.K., Nelson T.J. PKC signaling deficits: a mechanistic hypothesis of the origins of Alzheimer's disease. Trends Pharmacol Sci 2007, 28:51-60.
5. Allinson T.M., Parkin E.T., Turner A.J., Hooper N.M. ADAMS familiy members as amyloid precursor protein-alpha-secretases. J Neurosci Res 2003, 74:342-352.
6. Bar-Am O., Yogev-Falach M., Amit T., Sagi Y., Youdim B.H. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B, rasagiline and its derivatives, in vivo. J Neurochem 2004, 89:1119-1125.
7. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000, 163:495-529.
8. Bartus R.T., Dean R.L., Beer B., Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
9. Benussi L., Govoni S., Gasparini L., Binetti G., Trabucchi M., Bianchetti A., et al. Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid protein in human skin fibroblasts. Neurosci Lett 1998, 240:97-101.
10. Boix F., Fernández A., Escorihuela R.M a ., Tobeña A. Handling-habituation prevents the effects of diazepam and alprazolam on brain serotonin levels in rats. Behav Brain Res 1990, 36:209-215.
11. Buccafusco J.J., Terry A.V. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther 2000, 295:438-446.
12. Buxbaum J.D., Koo E.H., Greengard P. Protein phosphorilation inhibits production of Alzheimer amyloid β/A4 peptide. Proc Natl Acad Sci U S A 1993, 90:9195-9198.
13. Caccamo A., Oddo S., Billings L.M., Green K.N., Martínez-Coria H., Fisher A., et al. M1 Receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
14. Camps P., Cusack B., Mallender W.D., El Achab R., Morral J., Muñoz-Torrero D., et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000, 57:409-417.
15. Camps P., El Achab R., Morral J., Muñoz-Torrero D., Badia A., Baños J.E., et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem 2000, 43:4657-4666.
16. Carriero D.L., Outslay G., Mayorga A.J., Aberman J., Gianutsos G., Salamone J.D. Motor dysfunction produced by tacrine administration in rats. Pharmacol Biochem Behav 1997, 58:851-858.
17. Cheng D.H., Tang X.C. Comparative studies of huperzine A, E2020 and tacrine on behaviour and cholinesterase activities. Pharmacol Biochem Behav 1998, 60:377-386.
18. Desdouits-Magnen J., Desdouits F., Takeda S., Sy L.J., Saltiel A.R., Buxbaum J., et al. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 1998, 70:524-530.
19. Dong H., Csernansky C.A., Martin M.V., Bertchume A., Vallera D., Csernansky J.G. Acetylcholinesterase inhibitors ameloriate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology 2005, 181:145-152.
20. Giménez-Llort L., Fernández-Teruel A., Escorihuela R.M., Fredholm B., Tobeña A., Pekny M., et al. Mice lacking adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002, 16:547-550.
21. Giménez-Llort L., Blázquez G., Cañete T., Johansson B., Oddo S., Tobeña A., et al. A modeling behavioural and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007, 31:125-147.
22. Gray J.A., McNaughton N. The neuropsychology of anxiety 2000, Oxford University Press, Oxford.
23. Hallam K.T., Horgan J.E., McGrath C., Norman T.R. An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat. Behav Brain Res 2004, 153:481-486.
24. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 1999, 96:3922-3927.
25. Lang U.E., Lang F., Richter K., Vallon V., Lipp H.-P., Schnermann J., et al. Emotional inestability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav Brain Res 2003, 145:179-188.
26. Mayorga A.J., Carriero D.L., Cousind M.S., Gianutsos G., Salamone J.D. Tremulous jaw movements produced by acute tacrine administration: possible relation to parkinsonian side effects. Pharmacol Biochem Behav 1997, 56:273-279.
27. Mills J., Reiner P.B. Regulation of amyloid precursor protein cleavage. J Neurochem 1999, 72:443-460.
28. Mills J., Charest D.L., Lam F., Beyreuther K., Ida N., Pelech S.L., et al. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 1997, 17:9415-9422.
29. Nishizuka Y. The family of protein kinase C for signal transduction. J Am Med Assoc 1989, 262:1826-1833.
30. Nunan J., Small D.H. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 2000, 483:6-10.
31. Peng Y., Jiang L., Schanter S.C., Lee D.Y.W., Zhonge M., Lemere C.A. Effects of Huperzine A on amyloid precursor protein processing and β-amyloid generation in human embryonic kydney 293 APP Swedish mutant cells. J Neurosci Res 2006, 84:903-911.
32. Peng Y., Lee D.Y.W., Jiang L., Ma Z., Schachter S.C., Lemere C.A. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor. Neuroscience 2007, 150:386-395.
33. Racchi M., Mazzucchelli M., Sironi M., Govoni S. Role protein kinase Cα in the regulated secretion of the amyloid precursor protein. Mol Psychiatry 2003, 8:209-216.
34. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000, 54:2261-2268.
35. Román S., Vivas N.M., Badia A., Clos M a .V. Interaction of a new potent anticholinesterasic compound (+/-) huprine X with muscarinic receptors in rat brain. Neurosci Lett 2002, 325:103-106.
36. Román S., Badia A., Camps P., Clos M a .V a Potentiation effects of (+/-) huprine X, a new anticholinesterasic inhibitor, on nicotinic receptors in rat cortical synaptosomes. Neuropharmacology 2004, 46:95-102.
37. Ronco C., Sorin G., Nachon F., Foucoult R., Jean L., Romieu A., et al. Synthesis and structure-activity relationship of huprine derivatives as human acetylcholinesterase inhibitors. Bioorg Med Chem 2009, 17:4523-4545.
38. Schildein S., Huston J.P., Schwarting R.K. Injections of tacrine and scopolamine into the nucleus accumbens: opposing effects of immediate vs delayed posttrial treatment on memory of an open field. Neurobiol Learn Mem 2000, 72:21-30.
39. Steimer T., Driscoll P. Inter-individual vs line/strain differences in psychogenetically selected Roman High-(RHA) and Low-(RLA) Avoidance rats: neuroendocrine and behavioural aspects. Neurosci Biobehav Rev 2005, 29:99-112.
40. Sienkiewicz-Jarosz H., Maciejak P., Krzascik P., Cazlonkowska A.I., Szyndler J., Bidzinski A., et al. The effects of central administration of physostigmine in two models of anxiety. Pharmacol Biochem Behav 2003, 75:491-496.
41. Tang X.C., Han Y.F. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. CNS Drug Rev 1999, 5:281-300.
42. Van Dam D., De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 2006, 16:59-69.
43. Wang R., Zhang H.Y., Tang H.C. Huperzine attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein (1-40) in rat. Eur J Pharmacol 2001, 421:149-156.
44. Yogev-Falach M., Amir T., Bar-Am O., Weinstock M., Youdim M.B.H. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002, 16:1674-1676.
45. Zhang H.Y., Yan H., Tang X.C. Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells. Neurosci Lett 2004, 360:21-24.
46. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borrono B., Padovani A., et al. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem 2004, 90:1489-1499.